Helena Ribeiro

Pharmaceutical Development

The Pharmaceutical Development Lab aims to unravel new relevant drug delivery system strategies with the ability to make a difference in the promotion of a healthy society.

The activities of this specialized group are divided into three main research topics:

  • Development of innovative and sustainable drug delivery systems (DDS) and technologies, to be used in the prevention of diseases and optimization of treatments (cosmetics, medical devices and medicines);
  • Characterization of the target quality product;
  • Safe and efficacy studies – from lab to society.

Develop 3D tailored-made drug delivery systems using assisted Quality by Design (QbD) approaches

This project uses 3D printing to produce individualized drug load treatment platforms, adapted in shape and size to the patient.

This technology will repurpose the current therapeutic systems available on the market by modulating the drug release through advanced printing strategies.


Advanced topical Drug Delivery Systems (DDS) in skin diseases and in skin health

These projects are dedicated to developing novel DDS for skin delivery and targeting, with improved safety and efficacy, while minimizing side effects.

Projects with established drugs and substances have been performed using several DDS, taking advantage of their ease of use, speed, accessibility, and sustainability.

Individualized Drug Delivery Systems (DDS) – From Design to Clinic

The group is highly involved with the pharmaceutical industry and national hospitals, to ensure that the new developed products will be translated into healthcare pathways.

Quality characteristics of topical medicinal products through its marketing life cycle

The group has access to characterization tools that facilitate the management of the product’s life cycle, by monitoring its microstructure/physical properties, which are crucial for the product performance and usability.

Safe and efficacy studies – from lab to society

Clinical assessment of safety and efficacy of products/technologies, in accordance with national and international regulatory requirements, to allow the appropriate translation of academic research into people-centered healthcare.

Alves T, Arranca D, Martins AM, Ribeiro HM, Raposo S, Marto J. Study of equivalence of generic clotrimazole cream: complying with the guideline for quality and equivalence for topical semisolid products. Pharmaceutics 2021; 13: 555. DOI: 10.3390/pharmaceutics13040555
Chaves C, Marto J, Ramos FD, Alcobia A, Antunes L, Santos M, Bronze R, Ribeiro HM. Development of a Portuguese smell test: a novel hospital compounding formulation to improve diagnosis of olfactory dysfunction, submitted to J Sens Stud 2021; 36: e12617. DOI: 10.1111/joss.12617
Bom S, Santos C, Barros R, Martins AM, Paradiso P, Cláudio R, Pinto P, Ribeiro HM, Marto J. Effects of starch incorporation on the physicochemical properties and release kinetics of alginate-based 3D hydrogel patches for topical delivery, Pharmaceutics 2020; 12: 719. DOI: 10.3390/pharmaceutics12080719

Helena M. Ribeiro

Email: hribeiro@campus.ul.pt

Phone: (+351) 963 080 730

View Profile
Back To Top
Come meet us at

Faculdade de Farmácia da Universidade de Lisboa | Av. Professor Gama Pinto
1649-003 Lisboa | Portugal

Phone | +351 217 946 400
Fax | +351 217 946 470
Web | www.imed.ulisboa.pt
Email | imed.ulisboa@ff.ulisboa.pt